METHODS AND KITS THAT IDENTIFY TUMORS RESPONSIVE TO SRC INHIBITORS

摘要

Disclosed herein are methods of predicting whether or not a subject will benefit from treatment with a Src inhibitor on the basis of the expression of one or more of Von Hippel Lindau (VHL), Src, PTP1B, pFAK, HIF- 1a, and/or CA-IX in a tumor sample from the subject.